Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.

Trial Profile

Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Paricalcitol (Primary) ; Calcifediol
  • Indications Secondary hyperparathyroidism
  • Focus Therapeutic Use
  • Acronyms PARIDOINAL2013
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Oct 2015 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 25 Sep 2015 Planned end date changed from 1 Sep 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top